BriaCell Therapeutics Corp. SEC filings BCTXZ

BriaCell Therapeutics Corp. has 324 filings in SEC EDGAR's recent list, going back to Jun 20, 2014. Its latest annual report, Form 10-K, was filed on Oct 28, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 9, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Jun 26, 2026 (regulation fd disclosure). The company's fiscal year ends on July 31.

BriaCell Therapeutics Corp. SEC filings
Form Description Filed Period
DEF 14A Proxy statement Feb 12, 2026 Feb 12, 2026
DEFA14A Additional proxy material Jan 3, 2025 —
DEF 14A Proxy statement Dec 17, 2024 Dec 17, 2024
DEF 14A Proxy statement Jan 9, 2024 Jan 9, 2024
DEF 14A Proxy statement Jul 26, 2023 Jul 26, 2023
PRE 14A Preliminary proxy statement Jun 30, 2023 Jun 30, 2023
DEF 14A Proxy statement Jan 17, 2023 Jan 17, 2023
PRE 14A Preliminary proxy statement Jan 5, 2023 Jan 5, 2023

Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
BCTX (Nasdaq), BCTXL (Nasdaq), BCTXZ (Nasdaq)
Fiscal year ends
July 31
Incorporated in
British Columbia, Canada
Headquarters
West Vancouver, British Columbia, Canada
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1610820
Former names
Ansell Capital Corp. (until Jun 20, 2014)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.